APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)
NCT 03175224 Brief Summary To assess: efficacy of APL-101 as monotherapy for…
Read more arrow_forwardNCT 03175224 Brief Summary To assess: efficacy of APL-101 as monotherapy for…
Read more arrow_forwardNCT 05807035 Brief Summary Phase 1 trial to evaluate the feasibility of…
Read more arrow_forwardNCT 06106945 Brief Summary This is a Phase I/II, modular, open-label,…
Read more arrow_forwardNCT 06219941 Brief Summary The purpose of this study is to assess…
Read more arrow_forwardNCT 04924075 Brief Summary This is a study to evaluate the efficacy…
Read more arrow_forwardNCT 06120283 Brief Summary This is a dose escalation and dose expansion…
Read more arrow_forwardNCT 04918810 Brief Summary The purpose of this study is to see…
Read more arrow_forwardNCT 03522064 Brief Summary The purpose of this study is to determine…
Read more arrow_forwardNCT 05440786 Intervention / Treatment Drug: Abemaciclib Drug: Irinotecan Drug: Temozolomide Inclusion Criteria Diagnosis of…
Read more arrow_forwardNCT 04862663 Brief Summary A Phase Ib/III Open-label, Randomised Study of Capivasertib…
Read more arrow_forward